The Recall Desk
HighFDA (Drugs)·D-0404-2026·Announced 2026-04-01

Teva octreotide acetate 10 mg recalled over sterility assurance deficiencies

Teva is recalling two lots of Octreotide Acetate for Injectable Suspension 10 mg after quality system deficiencies were identified during an FDA inspection at the contract manufacturer.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported: this is an FDA Class II recall of an injectable medicine whose sterility cannot be assured, with no injuries stated.

Plain-English summary

Teva Pharmaceuticals USA, Inc is recalling Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, in single-dose 8 mL vial kits, prescription only, manufactured in Greece by Pharmathen International S.A., NDC 0480-9257-08. About 1,897 cartons were distributed nationwide in the United States. The FDA has classified this recall as Class II.

The recall was initiated for lack of assurance of sterility, following quality system deficiencies identified during a routine FDA inspection at the contract manufacturer.

Affected product covers lot 4401619 (expiry 09/30/2026) and lot 4501005 (expiry 03/31/2027).

Patients and pharmacies can identify affected product by the NDC and lot numbers above, and may contact Teva Pharmaceuticals USA, Inc for further information.

The recalled product

Product
OCTREOTIDE ACETATE (OCTREOTIDE ACETATE)
Brand
OCTREOTIDE ACETATE
Manufacturer
Teva Pharmaceuticals USA, Inc
Hazard
  • sterility-failure
  • infection-risk
  • injectable
  • quality-system-deficiency

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot: 4401619
  • Exp.: 09/30/2026
  • 4501005
  • 03/31/2027.

Distribution

Distributed nationwide across the United States.